Related Experiment Video
Updated: Jun 1, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Clinical study concerning anti-inflammatory effect of fixed dose therapy by budesonide/formoterol combination
Masayuki Hojo1, Tomonori Mizutani, Motoyasu Iikura
1Division of Respiratory Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan. mhojo@hosp.ncgm.go.jp
Background:
The clinical usefulness of fixed dose maintenance therapy using a combination inhaler containing budesonide and formoterol (FBC) has already been established, still evidence concerning anti-inflammatory effect by maintenance therapy with fix-dosed FBC, in comparison with other ICS and LABA combination therapy including salmeterol/fluticasone combination inhaler, is lacking.
Methods:
Moderate persistent adult asthmatics who has received combination therapy of ICS (200∼500 μg/day FP equivalent) and LABA (salmeterol 100 μg/day) for more than 6 months and under well-control conditions by asthma control test (ACT) have been recruited. FeNO, as a marker of airway inflammation, ACT score, and the results of spirometry have been evaluated after switching to maintenance therapy by FBC 640/18 μg/day for 8 weeks.
Results:
The fixed dosed FBC therapy resulted in superior primary outcome, as compared with previous ICS/LABA combination therapy, as assessed by measuring FeNO, 44.0±26.5 to 31.3± 15.4 ppb (p<0.01, paired-t test). ACT score also improved significantly, 22.22±1.57 to 23.88±1.57 (p<0.01). The number of patients who used SABA more than once a week has decreased 13 to 0 with FBC treatment.
Conclusion:
The airway anti-inflammatory effect by 8 weeks maintenance therapy with fix-dosed FBC 640/18 μg/day (2 puffs twice a day) has been strongly suggested.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma III: Clinical Manifestations
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...